Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies

被引:0
作者
Musa, Sanjin [1 ,2 ]
Baralija, Elma Catovic [3 ]
Sawin, Veronica Ivey [1 ]
Nardone, Anthony [4 ]
Palo, Mirza
Skocibusic, Sinisa [1 ]
Blazevic, Mia [1 ,5 ]
Lagarija, Seila Cilovic [1 ]
Ahmetovic-Karic, Gorana [3 ]
Ljuca, Alma [3 ]
Dostovic-Halilovic, Sanela [3 ]
Nedic, Rozalija [1 ]
Subissi, Lorenzo [6 ]
Ibrahim, Rawi [7 ]
Boshevska, Golubinka [7 ]
Bergeri, Isabel [6 ]
Pebody, Richard [7 ]
Vaughan, Aisling [7 ]
机构
[1] Inst Publ Hlth Federat Bosnia & Herzegovina, Sarajevo, Bosnia & Herceg
[2] Sarajevo Sch Sci & Technol, Sarajevo Med Sch, Sarajevo, Bosnia & Herceg
[3] Inst Transfus Med Federat Bosnia & Herzegovina, Sarajevo, Bosnia & Herceg
[4] Epiconcept, Paris, France
[5] World Hlth Org Off Bosnia & Herzegovina, Sarajevo, Bosnia & Herceg
[6] WHO, Geneva, Switzerland
[7] World Hlth Org Reg Off Europe, Copenhagen, Denmark
关键词
Bosnia and Herzegovina; cross-sectional study; longitudinal study; SARS-CoV-2; seroprevalence; UNITED-STATES;
D O I
10.1111/irv.13182
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundSarajevo Canton in the Federation of Bosnia and Herzegovina has recorded several waves of high SARS-CoV-2 transmission and has struggled to reach adequate vaccination coverage. We describe the evolution of infection- and vaccine-induced SARS-CoV-2 antibody response and persistence. MethodsWe conducted repeated cross-sectional analyses of blood donors aged 18-65 years in Sarajevo Canton in November-December 2020 and 2021. We analyzed serum samples for anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies. To assess immune durability, we conducted longitudinal analyses of seropositive participants at 6 and 12 months. ResultsOne thousand fifteen participants were included in Phase 1 (November-December 2020) and 1152 in Phase 2 (November-December 2021). Seroprevalence increased significantly from 19.2% (95% CI: 17.2%-21.4%) in Phase 1 to 91.6% (95% CI: 89.8%-93.1%) in Phase 2. Anti-S IgG titers were significantly higher among vaccinated (58.5%) than unvaccinated infected participants across vaccine products (p < 0.001), though highest among those who received an mRNA vaccine. At 6 months, 78/82 (95.1%) participants maintained anti-spike seropositivity; at 12 months, 58/58 (100.0%) participants were seropositive, and 33 (56.9%) had completed the primary vaccine series within 6 months. Among 11 unvaccinated participants who were not re-infected at 12 months, anti-S IgG declined from median 770.1 (IQR 615.0-1321.7) to 290.8 (IQR 175.7-400.3). Anti-N IgG antibodies waned earlier, from 35.4% seropositive at 6 months to 24.1% at 12 months. ConclusionsSARS-CoV-2 seroprevalence increased significantly over 12 months from end of 2020 to end of 2021. Although individuals with previous infection may have residual protection, COVID-19 vaccination is vital to strengthening population immunity.
引用
收藏
页数:10
相关论文
共 43 条
  • [1] A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States
    Alfego, David
    Sullivan, Adam
    Poirier, Brian
    Williams, Jonathan
    Adcock, Dorothy
    Letovsky, Stanley
    [J]. ECLINICALMEDICINE, 2021, 36
  • [2] Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
    Altarawneh, Heba N.
    Chemaitelly, Hiam
    Ayoub, Houssein H.
    Tang, Patrick
    Hasan, Mohammad R.
    Yassine, Hadi M.
    Al-Khatib, Hebah A.
    Smatti, Maria K.
    Coyle, Peter
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar H.
    Latif, Ali N.
    Shaik, Riyazuddin M.
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed G.
    Butt, Adeel A.
    Al-Romaihi, Hamad E.
    Al-Thani, Mohamed H.
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Abu-Raddad, Laith J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01) : 21 - 34
  • [3] Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
    Anand, Sai Priya
    Prevost, Jeremie
    Nayrac, Manon
    Beaudoin-Bussieres, Guillaume
    Benlarbi, Mehdi
    Gasser, Romain
    Brassard, Nathalie
    Laumaea, Annemarie
    Gong, Shang Yu
    Bourassa, Catherine
    Brunet-Ratnasingham, Elsa
    Medjahed, Halima
    Gendron-Lepage, Gabrielle
    Goyette, Guillaume
    Gokool, Laurie
    Morrisseau, Chantal
    Begin, Philippe
    Martel-Laferriere, Valerie
    Tremblay, Cecile
    Richard, Jonathan
    Bazin, Renee
    Duerr, Ralf
    Kaufmann, Daniel E.
    Finzi, Andres
    [J]. CELL REPORTS MEDICINE, 2021, 2 (06)
  • [4] Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]
  • [5] Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia
    Barchuk, Anton
    Shirokov, Daniil
    Sergeeva, Mariia
    Tursunzade, Rustam
    Dudkina, Olga
    Tychkova, Varvara
    Barabanova, Lubov
    Skougarevskiy, Dmitriy
    Danilenko, Daria
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (10) : 5846 - 5852
  • [6] Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis
    Bastos, Mayara Lisboa
    Tavaziva, Gamuchirai
    Abidi, Syed Kunal
    Campbell, Jonathon R.
    Haraoui, Louis -Patrick
    Johnston, James C.
    Lan, Zhiyi
    Law, Stephanie
    MacLean, Emily
    Trajman, Anete
    Menzies, Dick
    Benedetti, Andrea
    Khan, Faiz Ahmad
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 370
  • [7] Bergeri I., PRESCRIBER, DOI [10.1101/2021.12.14.21267791, DOI 10.1101/2021.12.14.21267791]
  • [8] Changing Age Distribution of the COVID-19 Pandemic - United States, May-August 2020
    Boehmer, Tegan K.
    DeVies, Jourdan
    Caruso, Elise
    van Santen, Katharina L.
    Tang, Shichao
    Black, Carla L.
    Hartnett, Kathleen P.
    Kite-Powell, Aaron
    Dietz, Stephanie
    Lozier, Matthew
    Gundlapalli, Adi, V
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2020, 69 (39): : 1404 - 1409
  • [9] SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline
    Bolotin, Shelly
    Tran, Vanessa
    Osman, Selma
    Brown, Kevin A.
    Buchan, Sarah A.
    Joh, Eugene
    Deeks, Shelley L.
    Allen, Vanessa G.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (08) : 1334 - 1338
  • [10] Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2